康龍化成新藥技術(shù)股份有限公司（股票代碼：300759.SZ / 3759.HK）是國(guó)際領(lǐng)先的生命科學(xué)研發(fā)服務(wù)企業(yè)。自2003年成立以來(lái)，康龍化成一直致力于其人才培養(yǎng)和設(shè)施建設(shè)，打造了一個(gè)貫穿合成與藥物化學(xué)、生物、藥物代謝及藥代動(dòng)力學(xué)、藥理、藥物安全評(píng)價(jià)、放射化學(xué)和放射標(biāo)記代謝、臨床藥理、臨床分析科學(xué)、臨床CRO及SMO、原料藥和制劑工藝開(kāi)發(fā)及其生產(chǎn)服務(wù)等各個(gè)領(lǐng)域的研發(fā)服務(wù)體系?？谍埢稍谥袊?guó)、美國(guó)、英國(guó)均開(kāi)展運(yùn)營(yíng)，擁有14,000多名員工，向北美、歐洲、日本和中國(guó)的合作伙伴提供研發(fā)解決方案并與之保持著良好的合作關(guān)系。

Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism, clinical pharmacology, clinical analytical sciences, clinical CRO and SMO, to chemical & pharmaceutical development. With over 14,000 employees, and operations in China, the United States, and the United Kingdom, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.